



PATENT  
Attorney Docket No.: 011823-004012US  
Client Reference No.: 004012 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Co et al.

Application No.: 10/084,825

Filed: February 25, 2002

For: INCREASING ANTIBODY  
AFFINITY BY ALTERING  
GLYCOSYLATION OF  
IMMUNOGLOBULIN VARIABLE  
REGION

Examiner: Larry Helms

Art Unit: 1642

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37  
CFR §1.97 and §1.98

---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that no fee is required for submission of this statement.


However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Joe Liebeschuetz  
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 650-326-2422  
JOL:crf  
60261100 v1



Substitute for form 1449A/PTO

*(use as many sheets as necessary)*

Sheet

1

of

2

**Complete if Known**

Application Number

10/084,825

Filing Date

February 25, 2002

First Named Inventor

Co, Man Sung

## Art Unit

1642

Examiner Name

**Larry Helms**

Attorney Docket Number

011823-004012US

## U.S. PATENT DOCUMENTS+

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner  
Signature**

Date  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

60261100 v1



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/084,825
				Filing Date	February 25, 2002
				First Named Inventor	Co, Man Sung
				Art Unit	1642
				Examiner Name	Larry Helms
Sheet	2	of	2	Attorney Docket Number	011823-004012US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AC	CO et al., "Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody," <u>Mol. Immunol.</u> , 30:1361 (1993).	
	AD	COLMA et al., "Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1-6) dextran antibody," <u>Jour. Immunol.</u> , 162:2162 (1999).	
	AE	GALA et al., "V region carbohydrate and antibody expression," <u>Jour. Immunol.</u> , 172:5494 (2004).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.